SCHEMBL5450024

SCHEMBL5450024

Cc1ccc2c(Nc3cc(CO)cc(NC(=O)C(C)N)c3)c3ccccc3nc2c1C

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 9/20 0.53
TOP2B Q02880 8/20 0.53
KDM1A O60341 6/20 0.48
CTSD P07339 2/20 0.46
PARP1 P09874 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
KDM4E B2RXH2 1/20 0.38
MITF O75030 1/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
MAPT P10636 1/20 0.38
RAD52 P43351 1/20 0.38
RECQL P46063 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3990042 1.00 TOP2A (0.53) TOP2ATOP2BKDM1ACTSDPARP1
SCHEMBL5404447 0.88 TOP2A (0.66) TOP2ATOP2BKDM1AKDM4EMITF
SCHEMBL3989825 0.88 TOP2A (0.66) TOP2ATOP2BKDM1AKDM4EMITF
SCHEMBL5428900 0.85 TOP2A (0.52) TOP2ATOP2BKDM1APARP1POLB
SCHEMBL3981078 0.85 TOP2A (0.52) TOP2ATOP2BKDM1APARP1POLB
SCHEMBL3984146 0.84 TOP2A (0.52) TOP2ATOP2BKDM1ACTSDKMT2A
SCHEMBL6545808 0.84 TOP2A (0.58) TOP2ATOP2BKDM1A
SCHEMBL5438138 0.84 TOP2A (0.58) TOP2ATOP2BKDM1A
SCHEMBL3983138 0.84 TOP2A (0.53) TOP2ATOP2BKDM1ACTSD
SCHEMBL3984667 0.81 TOP2A (0.64) TOP2ATOP2BKDM1AKDM4EMITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7230105-B2 9-aminoacridine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2007-06-12 US disclosed
US-20050222167-A1 9-aminoacridine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2005-10-06 US disclosed
EP-1487799-A4 9-AMINOACRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF SAMJIN PHARM CO LTD (KR) 2005-06-01 EP disclosed
EP-1487799-A1 9-AMINOACRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF Samjin Pharmaceutical Co., Ltd. (KR) 2004-12-22 EP disclosed
WO-2003074490-A1 9-AMINOACRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2003-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222167-A1 9-aminoacridine derivatives and process for the preparation thereof PARP9, CASP9, AMPD2 TOP2A 131/4885TOP2B 209/4885KDM1A 3000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.